Stockwatch: The Desert After The Bubble
This article was originally published in Scrip
Executive Summary
After the controversies surrounding drug pricing and specialty pharmacy channel stuffing it is no wonder that we are in the lackluster period after the bursting of the 2015 biotech bubble. Traditionally the aftermath of burst stock market bubbles can be associated with years in the investment wilderness, where generalist investors mostly avoid the sector.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.